Perseus Proteomics, Inc. · TSE:4882

Perseus Proteomics — H1 FY2027/3 Earnings Presentation

24 slides from Perseus Proteomics's earnings presentation, Nov 17, 2026

  1. Slide 1: FY2027/3 1st Half Business Results

    FY2027/3 1st Half Business Results Perseus Proteomics Inc. (Securities code: 4882) November 17, 20261

  2. Slide 2: Important Notice Regarding This Presentation

    Important Notice Regarding This Presentation • This material has been prepared based on information currently available to the Company. Statements regarding future business results contained in this material are forward-looking statements. Please note that these forward-looking statements are subjec

  3. Slide 3: Corporate philosophy

    Delivering technologies to enrich life in every corner of the world Corporate philosophy We contribute to global healthcare through cutting-edge antibody technology.

  4. Slide 4: Table of Contents

    Table of Contents 01 Business Activities 02 Q2 FY2027 Financial Results 03 Growth Strategy 44

  5. Slide 5: Business Activities

    PdPPina O01 Business Activities

  6. Slide 6: FY2027/3 Q2: Highlights

    FY2027/3 Q2: Highlights ① Entered into a joint research agreement with KYORIN Pharmaceutical aiming to create novel antibody therapeutics ② Completed the TOKYO Strategic Innovation Promotion Project ③ Held an IR event for individual shareholders 66

  7. Slide 7: Joint research agreement with KYORIN Pharmaceutical

    ①Entered into a joint research agreement with KYORIN Pharmaceutical aiming to create novel antibody therapeutics Joint KYORIN Pharmaceutical Research Perseus Proteomics A company striving to contribute broadly to Agreement A bioventure striving to discover and × people's health by providing new medi

  8. Slide 8: Completed the TOKYO Strategic Innovation Promotion Project

    ②Completed the TOKYO Strategic Innovation Promotion Project Enables flexible selection between two antibody generation technologies based on antigen characteristics Transitioning to business Rapid, high-efficiency generation of antibodies against difficult-to-target antigens—highly critical drug exp

  9. Slide 9: IR event for individual shareholders

    ③IR event for individual shareholders -Held the "2nd Nihonbashi Lab tour for individual shareholders" -Facilitated dialogue with shareholders to deepen understanding of our platform technologies <Event overview> Date & Time: Saturday, October 24, 2026 | 10:00–12:00 Location: Perseus Proteomics Headq

  10. Slide 10: FY2027/3: Plans and Progress through Q2

    FY2027/3: Plans and Progress through Q2 Plans Progress Out-licensing activities: PPMX-T003 / PPMX-T002 1 -Continue out-licensing activities • Out-licensing activities are ongoing for both pipelines Clinical development: PPMX-T003 2 -Complete investigator-initiated clinical trial for • Investigator-i

  11. Slide 11: Status of Out-Licensing Activities

    Status of Out-Licensing Activities PPMX-T003: ✓ To date, we have repeatedly approached pharmaceutical companies, biopharmaceutical companies, and venture capital firms in Europe, the United States, and Asia to explore potential out-licensing opportunities for PPMX-T003. ✓ We selected prospective par

  12. Slide 12: Development Pipeline Status

    Development Pipeline Status 1) Aggressive NK-cell leukemia 2) Radioisotope-labeled antibody 3) RI:90Y 4) RI:225Ac * Physician-initiated clinical trials are being conducted with the support of the AMED’s Pre-designation Practical Application Support Program for Orphan Drugs under the Drug Discovery S

  13. Slide 13: PPMX-T003: Progress Status in the Aggressive NK-Cell Leukemia Area

    PPMX-T003:Progress Status in the Aggressive NK-Cell Leukemia Area Hokkaido Tohoku Overview of the Investigator-Initiated Clinical Trial University University Hospital Kyoto University Hospital ⚫ Study design: Open-label, asymmetric, dose-escalation Hospital ⚫ Target disease: Aggressive NK-cell leuke

  14. Slide 14: Status of Drug Discovery Pipeline

    Status of Drug Discovery Pipeline 1) Antibody-drug conjugate 2) Bispecific antibody 3) IgG antibody 14 14

  15. Slide 15: PPMX-T004: Progress Status

    PPMX-T004:Progress Status Features and Current Status Efficacy Comparison of PPMX-T004b with Different DARs (DAR2, DAR4, and DAR8) and a Competing Product ⚫ An antibody-drug conjugate (ADC) targeting CDH3 ⚫ This drug is designed to bind strongly to CDH3 and then a b 2500 2500 PBS PBS be efficiently

  16. Slide 16: Q2 FY2027 Financial Results

    02 Q2 FY2027 Financial Results 16 16

  17. Slide 17: FY2027/3 Q2 Income Statement Summary

    FY2027/3 Q2 Income Statement Summary Income statement summary(Millions of yen) FY2026/3 Q2 FY2027/3 Q2 Antibody research support: JPY 7 million Results Results Antibody & reagent sales: JPY 45 million Net sales 60 52 Gross profit 57 47 SG&A 457 458 PPMX-T003 ANKL trial R&D cost 310 282 Fundamental t

  18. Slide 18: FY2027/3 Q2 Balance Sheet Summary

    FY2027/3 Q2 Balance Sheet Summary Balance sheet summary (Millions of yen) Assets Liabilities 2026/3/31 2026/9/30 2026/3/31 2026/9/30 Cash and Current 1,515 1,420 65 85 deposits liabilities Total current Non-current 1,608 1,491 340 390 assets liabilities Non-current 14 14 Total liabilities 405 476 as

  19. Slide 19: FY2027/3 Q2 Cash Flow Summary

    FY2027/3 Q2 Cash Flow Summary Cash flow statement (Millions of yen) FY2026/3 Q2 FY2027/3 Q2 Cash flows from operating activities △275 △292 Cash flows from investing activities △5 △1 Cash flows from financing activities △0 202 Effect of exchange rate change on cash △1 △4 and cash equivalents Net incr

  20. Slide 20: Growth Strategy

    PdPPina 03 Growth Strategy

  21. Slide 21: Business Development(1): Antibody Discovery Technology and AI-Driven Drug Discovery

    Business Development(1): Advancing Technology Through the Integration of Antibody Discovery Technology and AI-Driven Drug Discovery Enhancement Through Wet-Lab Strategy AI (Dry-Lab Approach) Emerging Technology Core Technologies Development ・Hybridoma ・De novo antibody generation ・Phage Display ・Imp

  22. Slide 22: Business Development(2): Expansion through Collaboration

    Business Development(2): Expansion through Collaboration Internal Resources ・Antibody discovery technologies leveraging our strengths in PPMX phage antibody libraries—including human and VHH libraries—and the ICOS method ・Experience in antibody evaluation, preclinical research, and clinical developm

  23. Slide 23: Business Development(3): Our Business Categories

    Business Development(3): Our Business Categories Drug Discovery Our core business New disease areas Proprietary Drug Discovery Using Future Internal Resources Expansion of Drug growth ・Targeting diseases such as cancer. Discovery Business ・Research, development, and out-licensing of New modalities o

  24. Slide 24: Contact us

    【Contact us】 Email: ir@ppmx.com https://www.ppmx.com

Perseus Proteomics — H1 FY2027/3 Earnings Presentation on 6ix